skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Individualized treatment of chronic hepatitis C with pegylated interferon and ribavirin

Review

(2471) Views  (950) Full article downloads

Authors: Roberto J Carvalho-Filho, Olav Dalgard

Published Date March 2010 Volume 2010:3 Pages 1 - 13
DOI: http://dx.doi.org/10.2147/PGPM.S4461

Roberto J Carvalho-Filho1, Olav Dalgard2

1Division of Gastroenterology, Hepatitis Section, Federal University of São Paulo, São Paulo, Brazil; 2Department of Medicine, Rikshospitalet, Oslo, Norway

Abstract: Chronic infection with hepatitis C virus (HCV) is a major public health problem, with perhaps 180 million people infected worldwide. A significant proportion of these will eventually develop clinical complications, such as cirrhosis, liver decompensation and hepatocellular carcinoma. Sustained virological response (SVR) to antiviral therapy is associated with improvement in liver histology and survival free of liver-related complications. Great effort has been made to improve SVR rate by adapting the duration of therapy according to HCV genotype and to on-treatment response. Rapid virological response (RVR, undetectable HCV RNA at week 4) usually has a high positive predictive value for achieving SVR and early virological response (EVR, ≥ 2 log reduction or undetectable HCV RNA at week 12) exhibits a high negative predictive value for non-response. Individualized approach can improve cost-effectiveness of HCV antiviral therapy by reducing side effects and the costs of therapy associated with unnecessary exposure to treatment and through extending therapy for those with unfavorable features. This article summarizes recent data on strategies of individualized treatment in naïve patients with mono-infection by the different HCV genotypes. The management of common side effects, the impact of HCV infection on health-related quality of life and the potential applications of host genomics in HCV therapy are also briefly discussed.

Keywords: hepatitis C, pegylated interferon, individualized treatment, genotype, genomics








Readers of this article also read:

Current management of type B aortic dissection
Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Pharmacogenomics in osteoporosis: Steps toward personalized medicine
Pharmacogenomics in type II diabetes mellitus management: Steps toward personalized medicine
Antiplatelet agents and proton pump inhibitors – personalizing treatment
Pharmacogenetics in breast cancer: steps toward personalized medicine in breast cancer management
Pharmacogenomics of drug metabolizing enzymes and transporters: implications for cancer therapy
A genetic approach to the prediction of drug side effects: bleomycin induces concordant phenotypes in mice of the collaborative cross
Cumulative clinical experience from over a decade of use of levofloxacin in community-acquired pneumonia: critical appraisal and role in therapy
The evolution of humor from male aggression